123.03
price up icon0.32%   0.39
pre-market  시장 영업 전:  122.55   -0.48   -0.39%
loading
전일 마감가:
$122.64
열려 있는:
$122.88
하루 거래량:
1.02M
Relative Volume:
0.69
시가총액:
$12.18B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
41.71
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
+2.05%
1개월 성능:
+15.56%
6개월 성능:
-2.81%
1년 성능:
-12.42%
1일 변동 폭
Value
$122.47
$124.30
1주일 범위
Value
$117.59
$124.30
52주 변동 폭
Value
$84.23
$157.98

뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile

Name
명칭
Neurocrine Biosciences Inc
Name
전화
(858) 617-7600
Name
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
직원
1,800
Name
트위터
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
NBIX's Discussions on Twitter

NBIX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
123.03 11.93B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.25 49.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
165.40 71.87B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.80 4.35M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.59 44.73B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.15 18.98B 16.54B -1.64B 749.00M -1.45

뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-15 업그레이드 Needham Hold → Buy
2025-04-14 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2025-02-11 개시 Deutsche Bank Hold
2024-10-10 재개 Raymond James Outperform
2024-08-29 업그레이드 Piper Sandler Neutral → Overweight
2024-04-24 업그레이드 Wells Fargo Equal Weight → Overweight
2023-12-13 재개 Citigroup Neutral
2023-12-12 개시 Deutsche Bank Buy
2023-10-24 재개 Cantor Fitzgerald Overweight
2023-08-21 재확인 Mizuho Neutral
2023-07-24 업그레이드 SVB Securities Market Perform → Outperform
2023-07-06 업그레이드 BMO Capital Markets Underperform → Market Perform
2023-05-04 업그레이드 Guggenheim Neutral → Buy
2023-03-30 업그레이드 Canaccord Genuity Hold → Buy
2023-03-03 업그레이드 Evercore ISI In-line → Outperform
2023-02-03 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-11-14 다운그레이드 Evercore ISI Outperform → In-line
2022-10-11 개시 UBS Buy
2022-09-26 개시 Wells Fargo Equal Weight
2022-06-06 재개 Jefferies Buy
2022-03-03 다운그레이드 Piper Sandler Overweight → Neutral
2022-02-25 업그레이드 Goldman Neutral → Buy
2022-01-18 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2021-11-19 개시 BMO Capital Markets Underperform
2021-11-17 업그레이드 JP Morgan Neutral → Overweight
2021-10-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-23 재개 Needham Hold
2021-08-06 다운그레이드 Canaccord Genuity Buy → Hold
2021-05-18 재개 Goldman Neutral
2021-05-06 업그레이드 Barclays Equal Weight → Overweight
2021-02-02 개시 Raymond James Outperform
2020-09-30 개시 The Benchmark Company Hold
2020-08-04 다운그레이드 JP Morgan Overweight → Neutral
2020-06-29 다운그레이드 Goldman Buy → Neutral
2020-06-09 개시 Wedbush Outperform
2020-03-06 개시 Citigroup Buy
2020-02-27 개시 Barclays Equal Weight
2020-02-24 개시 William Blair Outperform
2020-02-06 개시 Mizuho Neutral
2020-02-05 재확인 H.C. Wainwright Buy
2019-12-13 다운그레이드 Credit Suisse Outperform → Neutral
2019-08-07 개시 RBC Capital Mkts Outperform
2019-07-16 개시 Oppenheimer Outperform
2019-06-05 개시 Guggenheim Neutral
2019-05-21 개시 Credit Suisse Outperform
2019-04-22 업그레이드 JP Morgan Neutral → Overweight
2019-04-12 개시 Evercore ISI Outperform
2019-02-06 재확인 BofA/Merrill Buy
2019-01-23 다운그레이드 JP Morgan Overweight → Neutral
2018-12-13 개시 Goldman Buy
2018-11-21 개시 Canaccord Genuity Buy
모두보기

뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스

pulisher
12:06 PM

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - Yahoo

12:06 PM
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewswire Inc.

May 28, 2025
pulisher
May 28, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK

May 28, 2025
pulisher
May 28, 2025

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - PR Newswire

May 28, 2025
pulisher
May 25, 2025

Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia

May 25, 2025
pulisher
May 24, 2025

How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq

May 23, 2025
pulisher
May 20, 2025

Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourette Syndrome Treatment Market Detailed Analysis - openPR.com

May 20, 2025
pulisher
May 17, 2025

Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports lasting benefits of CRENESSITY in CAH study By Investing.com - Investing.com India

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study - Investing.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports progress for CAH drug as Voyager partnership shifts - The Pharma Letter

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports lasting benefits of CRENESSITY in CAH study - Investing.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting - PR Newswire

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia - WV News

May 16, 2025
pulisher
May 16, 2025

Groundbreaking One-Year Data: New Drug Reduces Steroid Use in Children with Rare Hormone Disorder - Stock Titan

May 16, 2025
pulisher
May 15, 2025

Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

90% Success Rate: CRENESSITY Shows Breakthrough Results in Congenital Adrenal Hyperplasia | NBIX Stock News - Stock Titan

May 15, 2025
pulisher
May 15, 2025

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) - PR Newswire

May 15, 2025
pulisher
May 14, 2025

Neurocrine (NBIX) Highlights Risks of High Glucocorticoid Doses in CAH Patients | NBIX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia - PR Newswire

May 14, 2025
pulisher
May 14, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Longview News-Journal

May 14, 2025
pulisher
May 14, 2025

New Research Reveals Dangerous Side Effects of High-Dose Steroids in CAH Treatment: What Doctors Need to Know - Stock Titan

May 14, 2025
pulisher
May 13, 2025

15 Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Neurocrine at BofA Conference: Strategic Moves and Market Challenges - Investing.com

May 13, 2025
pulisher
May 13, 2025

Learn to Evaluate (NBIX) using the Charts - news.stocktradersdaily.com

May 13, 2025
pulisher
May 13, 2025

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Neurocrine Biosciences To Present BofA Securities 2025 Health Care Conference; Webcast At 2:20 PM ET - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis - HCPLive

May 12, 2025
pulisher
May 12, 2025

Cognitive Impairment Associated with Schizophrenia Pipeline - openPR.com

May 12, 2025
pulisher
May 12, 2025

Cognitive Impairment Associated with Schizophrenia Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine - Barchart.com

May 12, 2025
pulisher
May 12, 2025

Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27% - simplywall.st

May 11, 2025
pulisher
May 10, 2025

Wedbush Lifts Earnings Estimates for Neurocrine Biosciences - Defense World

May 10, 2025
pulisher
May 09, 2025

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com

May 09, 2025
pulisher
May 09, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00 - Defense World

May 09, 2025
pulisher
May 09, 2025

Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - Defense World

May 09, 2025
pulisher
May 09, 2025

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

May 09, 2025
pulisher
May 08, 2025

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Neurocrine leans on singer Carnie Wilson for tardive dyskinesia push - Medical Marketing and Media

May 08, 2025
pulisher
May 08, 2025

Neurocrine Reports Late Stage Data Of Crenessity - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Neurocrine Biosciences, Inc. Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst?? Pediatric Study - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - MSN

May 08, 2025

뉴로크린 바이오사이언시스 (NBIX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_specialty_generic RDY
$14.56
price down icon 1.29%
drug_manufacturers_specialty_generic HCM
$13.23
price down icon 1.34%
$315.64
price up icon 0.25%
$8.59
price down icon 0.12%
$18.15
price up icon 2.48%
자본화:     |  볼륨(24시간):